胃肠间质瘤诊疗进展
Advances in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
DOI: 10.12677/acm.2026.163903, PDF,   
作者: 王伊璠, 邓晶今：延安大学医学院，陕西 延安；郝婷婷*：延安大学附属医院消化内科，陕西 延安
关键词: 胃肠道间质瘤；增强CT；超声内镜；影像组学；Gastrointestinal Stromal Tumor； Contrast-Enhanced CT； Endoscopic Ultrasonography； Radiomics
摘要: 胃肠间质瘤(GIST)诊断需结合临床表现(如胃肠道出血、腹痛等)、增强CT、超声内镜、MRI、影像组学等影像学检查以及CD117、CD34等免疫组化指标。治疗以手术治疗为核心，包括开腹、腹腔镜、内镜治疗及双镜联合、达芬奇辅助手术等；药物治疗以伊马替尼等酪氨酸激酶抑制剂(TKI)为主，涵盖术前新辅助、术后辅助及转移复发/不可切除病例的阶梯治疗，免疫靶向治疗等。随着分子生物学的发展，对GIST的理解日益深入，GIST的多种诊断技术和治疗都有了新的进展，特别是在个体化、精准医疗和靶向治疗方面有极大的进步。
Abstract: The diagnosis of gastrointestinal stromal tumor (GIST) requires a combination of clinical manifestations (such as gastrointestinal bleeding, abdominal pain, etc.), imaging examinations including contrast-enhanced computed tomography (CT), endoscopic ultrasonography (EUS), magnetic resonance imaging (MRI) and radiomics, as well as immunohistochemical markers such as CD117 and CD34. Surgery serves as the core of treatment, including open surgery, laparoscopic surgery, endoscopic therapy, combined dual-endoscopy surgery and da Vinci robot-assisted surgery. Pharmacotherapy is mainly based on tyrosine kinase inhibitors (TKIs) such as imatinib, covering preoperative neoadjuvant therapy, postoperative adjuvant therapy, stepwise therapy for metastatic/recurrent or unresectable cases, and immune-targeted therapy. With the development of molecular biology, the understanding of GIST has been increasingly in-depth, and various diagnostic techniques and treatments for GIST have achieved new progress, especially great advances in individualized and precision medicine as well as targeted therapy.
文章引用：王伊璠, 邓晶今, 郝婷婷. 胃肠间质瘤诊疗进展[J]. 临床医学进展, 2026, 16(3): 1258-1267. https://doi.org/10.12677/acm.2026.163903

参考文献

[1] Søreide, K., Sandvik, O.M., Søreide, J.A., Giljaca, V., Jureckova, A. and Bulusu, V.R. (2016) Global Epidemiology of Gastrointestinal Stromal Tumours (GIST): A Systematic Review of Population-Based Cohort Studies. Cancer Epidemiology, 40, 39-46. [Google Scholar] [CrossRef] [PubMed]
[2] von Mehren, M. and Joensuu, H. (2018) Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 36, 136-143. [Google Scholar] [CrossRef] [PubMed]
[3] DeMatteo, R.P., Gold, J.S., Saran, L., Gönen, M., Liau, K.H., Maki, R.G., et al. (2007) Tumor Mitotic Rate, Size, and Location Independently Predict Recurrence after Resection of Primary Gastrointestinal Stromal Tumor (GIST). Cancer, 112, 608-615. [Google Scholar] [CrossRef] [PubMed]
[4] Blay, J., Kang, Y., Nishida, T. and von Mehren, M. (2021) Gastrointestinal Stromal Tumours. Nature Reviews Disease Primers, 7, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[5] Nishida, T., Blay, J., Hirota, S., Kitagawa, Y. and Kang, Y. (2015) The Standard Diagnosis, Treatment, and Follow-Up of Gastrointestinal Stromal Tumors Based on Guidelines. Gastric Cancer, 19, 3-14. [Google Scholar] [CrossRef] [PubMed]
[6] Joensuu, H., Hohenberger, P. and Corless, C.L. (2013) Gastrointestinal Stromal Tumour. The Lancet, 382, 973-983. [Google Scholar] [CrossRef] [PubMed]
[7] Martin-Broto, J., Martinez-Marín, V., Serrano, C., Hindi, N., López-Guerrero, J.A., Ramos-Asensio, R., et al. (2016) Gastrointestinal Stromal Tumors (GISTS): SEAP-SEOM Consensus on Pathologic and Molecular Diagnosis. Clinical and Translational Oncology, 19, 536-545. [Google Scholar] [CrossRef] [PubMed]
[8] Valsangkar, N., Sehdev, A., Misra, S., Zimmers, T.A., O’Neil, B.H. and Koniaris, L.G. (2015) Current Management of Gastrointestinal Stromal Tumors: Surgery, Current Biomarkers, Mutations, and Therapy. Surgery, 158, 1149-1164. [Google Scholar] [CrossRef] [PubMed]
[9] 桑节峰, 韩磊, 李大鹏, 等. 多层螺旋CT增强在胃肠道间质瘤治疗前评估中的价值[J]. 中国CT和MRI杂志, 2023, 21(11): 125-127.
[10] Li, C., Fu, W., Huang, L., Chen, Y., Xiang, P., Guan, J., et al. (2021) A CT-Based Nomogram for Predicting the Malignant Potential of Primary Gastric Gastrointestinal Stromal Tumors Preoperatively. Abdominal Radiology, 46, 3075-3085. [Google Scholar] [CrossRef] [PubMed]
[11] Jung, H., Lee, S.M., Kim, Y.C., Byun, J., Park, J.Y., Oh, B.Y., et al. (2022) Gastrointestinal Stromal Tumours: Preoperative Imaging Features to Predict Recurrence after Curative Resection. European Journal of Radiology, 149, Article 110193. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, X., Yuan, W., Xu, Z., Yang, Y., Dong, S., Liu, L., et al. (2022) Prognostic Value of Preoperative CT Features for Disease-Free Survival in Patients with Primary Gastric Gastrointestinal Stromal Tumors after Resection. Abdominal Radiology, 48, 494-501. [Google Scholar] [CrossRef] [PubMed]
[13] 尹晓南, 蔡兆伦, 沈朝勇, 等. 能谱CT在胃肠间质瘤中的应用进展[J]. 中华普通外科学文献(电子版), 2025, 19(6): 402-408.
[14] 陈楠, 叶德胜, 邓满红. 能谱CT成像对胃黏膜下微小病变检出率的应用价值[J]. 现代医用影像学, 2024, 33(5): 858-861.
[15] Grazzini, G., Guerri, S., Cozzi, D., Danti, G., Gasperoni, S., Pradella, S., et al. (2021) Gastrointestinal Stromal Tumors: Relationship between Preoperative CT Features and Pathologic Risk Stratification. Tumori Journal, 107, 556-563. [Google Scholar] [CrossRef] [PubMed]
[16] Meyer, M., Ota, H., Messiou, C., Benson, C., Henzler, T., Mattonen, S.A., et al. (2024) Prospective Evaluation of Quantitative Response Parameter in Patients with Gastrointestinal Stroma Tumor Undergoing Tyrosine Kinase Inhibitor Therapy—Impact on Clinical Outcome. International Journal of Cancer, 155, 2047-2057. [Google Scholar] [CrossRef] [PubMed]
[17] Nishida, T., Kawai, N., Yamaguchi, S. and Nishida, Y. (2013) Submucosal Tumors: Comprehensive Guide for the Diagnosis and Therapy of Gastrointestinal Submucosal Tumors. Digestive Endoscopy, 25, 479-489. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, T., Hsu, C., Chu, Y., Wu, C., Chen, T., Hsu, J., et al. (2015) Association of Endoscopic Ultrasonographic Parameters and Gastrointestinal Stromal Tumors (GISTS): Can Endoscopic Ultrasonography Be Used to Screen Gastric Gists for Potential Malignancy? Scandinavian Journal of Gastroenterology, 51, 374-377. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, L., Chen, J., Shan, J. and Sun, X. (2023) Development and Validation of an EUS-Based Nomogram for Prediction of the Malignant Potential in Gastrointestinal Stromal Tumors. Scandinavian Journal of Gastroenterology, 58, 830-837. [Google Scholar] [CrossRef] [PubMed]
[20] Mi, J., Wang, J., Liu, J., Zhang, L., Du, H. and Zhao, D. (2021) The Value of Endoscopic Ultrasonography in the Endoscopic Resection of Gastrointestinal Stromal Tumors. International Journal of General Medicine, 14, 5149-5157. [Google Scholar] [CrossRef] [PubMed]
[21] Sekine, M., Asano, T. and Mashima, H. (2022) The Diagnosis of Small Gastrointestinal Subepithelial Lesions by Endoscopic Ultrasound-Guided Fine Needle Aspiration and Biopsy. Diagnostics, 12, Article 810. [Google Scholar] [CrossRef] [PubMed]
[22] Lanke, G. and Lee, J.H. (2017) How Best to Manage Gastrointestinal Stromal Tumor. World Journal of Clinical Oncology, 8, 135. [Google Scholar] [CrossRef] [PubMed]
[23] Yoo, J., Kim, S.H. and Han, J.K. (2019) Multiparametric MRI and 18F-FDG PET Features for Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Subepithelial Lesions. European Radiology, 30, 1634-1643. [Google Scholar] [CrossRef] [PubMed]
[24] Zheng, T., Du, J., Yang, L., Dong, Y., Wang, Z., Liu, D., et al. (2020) Evaluation of Risk Classifications for Gastrointestinal Stromal Tumor Using Multi-Parameter Magnetic Resonance Analysis. Abdominal Radiology, 46, 1506-1518. [Google Scholar] [CrossRef] [PubMed]
[25] Li, S., Lin, D., Tang, M., Liu, D., Lyu, Q. and Zhang, J. (2022) Value of 18F-FDG PET/CT for Differentiating Diagnosis between Malignant and Benign Primary Gastric Gastrointestinal Mesenchymal Tumors: A Single-Center Retrospective Study. Journal of Gastrointestinal Oncology, 13, 637-646. [Google Scholar] [CrossRef] [PubMed]
[26] Du, W., Cui, G., Wang, K. and Li, S. (2022) Clinical Significance of 18F-FDG PET/CT Imaging in 32 Cases of Gastrointestinal Stromal Tumors. European Journal of Medical Research, 27, Article No. 182. [Google Scholar] [CrossRef] [PubMed]
[27] Albano, D., Bosio, G., Tomasini, D., Bonù, M., Giubbini, R. and Bertagna, F. (2020) Metabolic Behavior and Prognostic Role of Pretreatment 18F‐FDG PET/CT in Gist. Asia-Pacific Journal of Clinical Oncology, 16, e207-e215. [Google Scholar] [CrossRef] [PubMed]
[28] Dimitrakopoulou-Strauss, A., Ronellenfitsch, U., Cheng, C., Pan, L., Sachpekidis, C., Hohenberger, P., et al. (2017) Imaging Therapy Response of Gastrointestinal Stromal Tumors (GIST) with FDG PET, CT and MRI: A Systematic Review. Clinical and Translational Imaging, 5, 183-197. [Google Scholar] [CrossRef] [PubMed]
[29] Zhu, C., Hua, Y., Zhang, M., Wang, Y., Li, W., Ding, Y., et al. (2022) A Multimodal Multipath Artificial Intelligence System for Diagnosing Gastric Protruded Lesions on Endoscopy and Endoscopic Ultrasonography Images. Clinical and Translational Gastroenterology, 14, e00551. [Google Scholar] [CrossRef] [PubMed]
[30] Jia, X., Wan, L., Chen, X., Ji, W., Huang, S., Qi, Y., et al. (2022) Risk Stratification for 1-To 2-Cm Gastric Gastrointestinal Stromal Tumors: Visual Assessment of CT and EUS High-Risk Features versus CT Radiomics Analysis. European Radiology, 33, 2768-2778. [Google Scholar] [CrossRef] [PubMed]
[31] Ji, X., Shang, Y., Tan, L., Hu, Y., Liu, J., Song, L., et al. (2024) Prediction of High-Risk Gastrointestinal Stromal Tumor Recurrence Based on Delta-CT Radiomics Modeling: A 3-Year Follow-Up Study after Surgery. Clinical Medicine Insights: Oncology, 18, 1-10. [Google Scholar] [CrossRef] [PubMed]
[32] 毛俊, 蔡兆伦, 尹晓南, 等. 影像组学预测模型在胃肠间质瘤诊断及预后中的研究进展[J]. 中华普通外科学文献(电子版), 2025, 19(6): 421-425.
[33] Bleckman, R.F., Haag, C.M.S.C., Rifaela, N., Beukema, G., Mathijssen, R.H.J., Steeghs, N., et al. (2024) Levels of Circulating Tumor DNA Correlate with Tumor Volume in Gastro‐intestinal Stromal Tumors: An Exploratory Long‐Term Follow‐up Study. Molecular Oncology, 18, 2658-2667. [Google Scholar] [CrossRef] [PubMed]
[34] Rassner, M., Waldeck, S., Follo, M., Jilg, S., Philipp, U., Jolic, M., et al. (2023) Development of Highly Sensitive Digital Droplet PCR for Detection of CKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST). International Journal of Molecular Sciences, 24, Article 5411. [Google Scholar] [CrossRef] [PubMed]
[35] Serrano, C., Bauer, S., Gómez-Peregrina, D., Kang, Y.-., Jones, R.L., Rutkowski, P., et al. (2023) Circulating Tumor DNA Analysis of the Phase III VOYAGER Trial: KIT Mutational Landscape and Outcomes in Patients with Advanced Gastrointestinal Stromal Tumor Treated with Avapritinib or Regorafenib. Annals of Oncology, 34, 615-625. [Google Scholar] [CrossRef] [PubMed]
[36] Brinch, C.M., Aggerholm-Pedersen, N., Poulsen, T.S., Skovrider-Ruminski, W., de Heer, P., Penninga, L., et al. (2022) Pre-and Postoperative Circulating Tumour DNA in Patients with Gastrointestinal Stromal Tumour—A Methodological Assessment Study. Anticancer Research, 42, 5527-5537. [Google Scholar] [CrossRef] [PubMed]
[37] Zhao, X. and Yue, C. (2012) Gastrointestinal Stromal Tumor. Journal of Gastrointestinal Oncology, 3, 189-208.
[38] Dei Tos, A.P., Hornick, J.L., Miettinen, M., Wanless, I.R. and Wardelmann, E. (2020) Gastrointestinal Stromal Tumour. In: The WHO Classification of Tumours Editorial Board, Ed., WHO Classification of Tumours Soft Tissue and Bone Tumours, 5th Edition, IARC Press, 216-221.
[39] Hirota, S. (2018) Differential Diagnosis of Gastrointestinal Stromal Tumor by Histopathology and Immunohistochemistry. Translational Gastroenterology and Hepatology, 3, 27-27. [Google Scholar] [CrossRef] [PubMed]
[40] Nishida, T., Naito, Y., Takahashi, T., Saito, T., Hisamori, S., Manaka, D., et al. (2024) Molecular and Clinicopathological Features of KIT/PDGFRA Wild‐Type Gastrointestinal Stromal Tumors. Cancer Science, 115, 894-904. [Google Scholar] [CrossRef] [PubMed]
[41] Swalchick, W., Shamekh, R. and Bui, M.M. (2015) Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor? Cancer Control, 22, 498-504. [Google Scholar] [CrossRef] [PubMed]
[42] Lin, J., Huang, C., Zheng, C., Li, P., Xie, J., Wang, J., et al. (2014) Laparoscopic versus Open Gastric Resection for Larger than 5 Cm Primary Gastric Gastrointestinal Stromal Tumors (GIST): A Size-Matched Comparison. Surgical Endoscopy, 28, 2577-2583. [Google Scholar] [CrossRef] [PubMed]
[43] Nishida, T., Goto, O., Raut, C.P. and Yahagi, N. (2016) Diagnostic and Treatment Strategy for Small Gastrointestinal Stromal Tumors. Cancer, 122, 3110-3118. [Google Scholar] [CrossRef] [PubMed]
[44] Lian, X., Feng, F., Guo, M., Cai, L., Liu, Z., Liu, S., et al. (2017) Meta-Analysis Comparing Laparoscopic versus Open Resection for Gastric Gastrointestinal Stromal Tumors Larger than 5 Cm. BMC Cancer, 17, Article No. 760. [Google Scholar] [CrossRef] [PubMed]
[45] Goh, B.K.P., Chow, P.K.H., Chok, A., Chan, W., Chung, Y.A., Ong, H., et al. (2010) Impact of the Introduction of Laparoscopic Wedge Resection as a Surgical Option for Suspected Small/medium‐sized Gastrointestinal Stromal Tumors of the Stomach on Perioperative and Oncologic Outcomes. World Journal of Surgery, 34, 1847-1852. [Google Scholar] [CrossRef] [PubMed]
[46] MacArthur, K.M., Baumann, B.C. and Nicholl, M.B. (2016) Laparoscopic versus Open Resection for Gastrointestinal Stromal Tumors (GISTS). Journal of Gastrointestinal Cancer, 48, 20-24. [Google Scholar] [CrossRef] [PubMed]
[47] Chen, K., Zhou, Y., Mou, Y., Xu, X., Jin, W. and Ajoodhea, H. (2014) Systematic Review and Meta-Analysis of Safety and Efficacy of Laparoscopic Resection for Gastrointestinal Stromal Tumors of the Stomach. Surgical Endoscopy, 29, 355-367. [Google Scholar] [CrossRef] [PubMed]
[48] Schmidt, T., Ghadimi, M., Fuchs, H.F. and Bruns, C.J. (2022) Chirurgische und interdisziplinäre Therapie gastrointestinaler Stromatumoren. Der Chirurg, 93, 27-33. [Google Scholar] [CrossRef] [PubMed]
[49] An, W., Sun, P., Gao, J., Jiang, F., Liu, F., Chen, J., et al. (2017) Endoscopic Submucosal Dissection for Gastric Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Surgical Endoscopy, 31, 4522-4531. [Google Scholar] [CrossRef] [PubMed]
[50] Liu, Z., Zeng, Z., Ouyang, S., Zhang, Z., Sun, J., Wang, X., et al. (2021) Comparison among Endoscopic, Laparoscopic, and Open Resection for Relatively Small Gastric Gastrointestinal Stromal Tumors (<5 Cm): A Bayesian Network Meta-analysis. Frontiers in Oncology, 11, Article ID: 672364. [Google Scholar] [CrossRef] [PubMed]
[51] Zhang, Y., Mao, X., Zhou, X., Yang, H., Chen, L.Z.G. and Ye, L. (2018) Long-Term Outcomes of Endoscopic Resection for Small (≤ 4.0 Cm) Gastric Gastrointestinal Stromal Tumors Originating from the Muscularis Propria Layer. World Journal of Gastroenterology, 24, 3030-3037. [Google Scholar] [CrossRef] [PubMed]
[52] Zhu, H., Zhao, S., Jiao, R., Zhou, J., Zhang, C. and Miao, L. (2020) Comparison of Endoscopic versus Laparoscopic Resection for Gastric Gastrointestinal Stromal Tumors: A Preliminary Meta‐Analysis. Journal of Gastroenterology and Hepatology, 35, 1858-1868. [Google Scholar] [CrossRef] [PubMed]
[53] Hoteya, S., Haruta, S., Shinohara, H., Yamada, A., Furuhata, T., Yamashita, S., et al. (2013) Feasibility and Safety of Laparoscopic and Endoscopic Cooperative Surgery for Gastric Submucosal Tumors, Including Esophagogastric Junction Tumors. Digestive Endoscopy, 26, 538-544. [Google Scholar] [CrossRef] [PubMed]
[54] Hiki, N. and Nunobe, S. (2019) Laparoscopic Endoscopic Cooperative Surgery (LECS) for the Gastrointestinal Tract: Updated Indications. Annals of Gastroenterological Surgery, 3, 239-246. [Google Scholar] [CrossRef] [PubMed]
[55] Hashimoto, Y., Abe, N., Nunobe, S., Kawakubo, H., Sumiyoshi, T., Yoshida, N., et al. (2024) Outcomes of Laparoscopic and Endoscopic Cooperative Surgery for Gastric Submucosal Tumors: A Retrospective Multicenter Study at 21 Japanese Institutions. Annals of Gastroenterological Surgery, 8, 778-786. [Google Scholar] [CrossRef] [PubMed]
[56] Namikawa, T. and Hanazaki, K. (2015) Laparoscopic Endoscopic Cooperative Surgery as a Minimally Invasive Treatment for Gastric Submucosal Tumor. World Journal of Gastrointestinal Endoscopy, 7, 1150-1156. [Google Scholar] [CrossRef] [PubMed]
[57] Ceccarelli, G., Costa, G., De Rosa, M., Codacci Pisanelli, M., Frezza, B., De Prizio, M., et al. (2021) Minimally Invasive Approach to Gastric Gists: Analysis of a Multicenter Robotic and Laparoscopic Experience with Literature Review. Cancers, 13, Article 4351. [Google Scholar] [CrossRef] [PubMed]
[58] Jian, C., Huang, X., Lin, R., Yang, W., Zheng, S., He, H., et al. (2024) Robot-Assisted Laparoscopic Combined with Endoscopic Partial Gastrectomy (RALE-PG) for the Treatment of Gastric Gastrointestinal Stromal Tumors in Challenging Anatomical Locations: Single-Center Experience. Frontiers in Surgery, 11, Article ID: 1391387. [Google Scholar] [CrossRef] [PubMed]
[59] Balachandran, V.P. and DeMatteo, R.P. (2014) Gastrointestinal Stromal Tumors. Advances in Surgery, 48, 165-183. [Google Scholar] [CrossRef] [PubMed]
[60] Jakob, J. and Hohenberger, P. (2018) Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. Visceral Medicine, 34, 359-365. [Google Scholar] [CrossRef] [PubMed]
[61] Joseph, C.P., Abaricia, S.N., Angelis, M.A., Polson, K., Jones, R.L., Kang, Y., et al. (2021) Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. The Oncologist, 26, e622-e631. [Google Scholar] [CrossRef] [PubMed]
[62] Joensuu, H., Wardelmann, E., Sihto, H., Eriksson, M., Sundby Hall, K., Reichardt, A., et al. (2017) Effect of KIT and PDGFRA Mutations on Survival in Patients with Gastrointestinal Stromal Tumors Treated with Adjuvant Imatinib. JAMA Oncology, 3, 602-609. [Google Scholar] [CrossRef] [PubMed]
[63] DeMatteo, R.P., Ballman, K.V., Antonescu, C.R., Corless, C., Kolesnikova, V., von Mehren, M., et al. (2013) Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. Annals of Surgery, 258, 422-429. [Google Scholar] [CrossRef] [PubMed]
[64] Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J.T., Pink, D., Schütte, J., et al. (2012) One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. JAMA, 307, 1265-1272. [Google Scholar] [CrossRef] [PubMed]
[65] Raut, C.P., Espat, N.J., Maki, R.G., Araujo, D.M., Trent, J., Williams, T.F., et al. (2018) Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients with Resected Intermediate-or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncology, 4, e184060. [Google Scholar] [CrossRef] [PubMed]
[66] von Mehren, M., Kane, J.M., Riedel, R.F., Sicklick, J.K., Pollack, S.M., Agulnik, M., et al. (2022) NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. Journal of the National Comprehensive Cancer Network, 20, 1204-1214. [Google Scholar] [CrossRef] [PubMed]
[67] Florindez, J. and Trent, J. (2020) Low Frequency of Mutation Testing in the United States. American Journal of Clinical Oncology, 43, 270-278. [Google Scholar] [CrossRef] [PubMed]
[68] Demetri, G.D., Reichardt, P., Kang, Y., Blay, J., Rutkowski, P., Gelderblom, H., et al. (2013) Efficacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 295-302. [Google Scholar] [CrossRef] [PubMed]
[69] Smith, B.D., Kaufman, M.D., Lu, W., Gupta, A., Leary, C.B., Wise, S.C., et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 35, 738-751.e9. [Google Scholar] [CrossRef] [PubMed]
[70] Blay, J., Serrano, C., Heinrich, M.C., Zalcberg, J., Bauer, S., Gelderblom, H., et al. (2020) Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumours (INVICTUS): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 923-934. [Google Scholar] [CrossRef] [PubMed]
[71] Heinrich, M.C., Jones, R.L., von Mehren, M., Schöffski, P., Serrano, C., Kang, Y., et al. (2020) Avapritinib in Advanced PDGFRA D842v-Mutant Gastrointestinal Stromal Tumour (NAVIGATOR): A Multicentre, Open-Label, Phase 1 Trial. The Lancet Oncology, 21, 935-946. [Google Scholar] [CrossRef] [PubMed]
[72] Doi, T., Kurokawa, Y., Sawaki, A., Komatsu, Y., Ozaka, M., Takahashi, T., et al. (2019) Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial. European Journal of Cancer, 121, 29-39. [Google Scholar] [CrossRef] [PubMed]
[73] Iida, K., Abdelhamid Ahmed, A.H., Nagatsuma, A.K., Shibutani, T., Yasuda, S., Kitamura, M., et al. (2021) Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with Ds-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discovery, 11, 1508-1523. [Google Scholar] [CrossRef] [PubMed]

为你推荐